166 related articles for article (PubMed ID: 37658924)
1. Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients.
Paal K; Stranz B; Thurner EM; Langsenlehner U; Renner W; Brunner TB; Langsenlehner T
Strahlenther Onkol; 2024 Mar; 200(3):208-218. PubMed ID: 37658924
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
3. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.
Stankovic V; Džamic Z; Pekmezovic T; Tepavcevic DK; Dozic M; Saric M; Vuckovic S; Nikitovic M
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):577-86. PubMed ID: 27184943
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
5. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus: a predictor for late radiation morbidity.
Herold DM; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):475-9. PubMed ID: 10078625
[TBL] [Abstract][Full Text] [Related]
7. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
8. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
[TBL] [Abstract][Full Text] [Related]
9. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
[TBL] [Abstract][Full Text] [Related]
10. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
12. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
13. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
[TBL] [Abstract][Full Text] [Related]
14. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
[TBL] [Abstract][Full Text] [Related]
15. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of the lower gastrointestinal tract and its predictive factors after 72Gy conventionally fractionated 3D conformal radiotherapy of localized prostate cancer.
Stankovic V; Nikitovic M; Pekmezovic T; Pekmezovic D; Kisic Tepavcevic D; Stefanovic Djuric A; Saric M
J BUON; 2016; 21(5):1224-1232. PubMed ID: 27837627
[TBL] [Abstract][Full Text] [Related]
17. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
20. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]